Medexus Pharmaceuticals Inc (MDP) AI Stock Analysis

• Market Cap: C$101.75M
• Dividend Yield: N/A
• Average Volume (3M): 46.68K
• Price to Earnings (P/E): 211.5
• Beta (1Y): 0.91
• Revenue Growth: 2.14%
• EPS Growth: -83.06%
• Country: CA
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 32,300,380
• 10 Day Avg. Volume: 30,861
• 30 Day Avg. Volume: 46,683
• PEG Ratio: 1.50
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.32
• P/FCF Ratio: 1.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$6.00
• Price Target Upside: 90.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): C$100.34M

• Rating: 68 Neutral
• Price Target: C$3.50 ▲(11.11% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily supported by improved financial quality—strong TTM free cash flow and a meaningfully deleveraged balance sheet—plus constructive price trend signals. It is held back by weak earnings-based valuation (negative P/E) and earnings-call risks around YoY revenue/earnings pressure and near-term launch investment drag despite improving GRAFAPEX adoption and guidance.

Positive Factors

Cash generation

Sustained TTM operating and free cash flow near $17M provides durable internal funding to reduce debt, fund launches and buybacks, and absorb temporary revenue variability. Strong cash conversion supports strategic flexibility and lowers reliance on external financing over the next 2–6 months.

Deleveraging & liquidity

Material deleveraging from prior high leverage to ~0.4 D/E and a credit facility that reduced quarterly principal repayments improves financial stability. Lower debt servicing and smaller principal obligations give the company durable runway to scale commercialization without near-term refinancing pressure.

GRAFAPEX commercial traction

Early adoption with one-third of transplant centers ordering and a high reorder rate indicates product-market fit in a targeted specialty channel. The nine‑month $8.2M base and management guidance to $11–$12M for FY26 create a repeatable revenue runway that can sustainably accrete cash flow as penetration grows.

Negative Factors

Revenue contraction risk

A meaningful YoY revenue decline driven by generic competition and loss/return of licensed products shows the business remains exposed to product-specific shocks. Structural revenue erosion from competitors or licensors forces reliance on successful launches to replace lost cash flows, heightening execution risk.

Fragile profitability

Modest EBITDA and near‑breakeven net income indicate limited earnings cushion. With returns on equity low and profitability fragile, margin compression or slower product adoption could quickly reverse progress, constraining reinvestment, R&D/licensing, and the ability to build durable operating leverage.

Capital intensity of launches

Launch spending slightly exceeding early product revenue and a ~37% drop in cash on hand highlight the capital intensity and timing risk of commercialization. If ramp pacing or wholesaler recognition lags persist, liquidity could tighten and necessitate additional funding or slower expansion to sustain commercialization efforts.

Medexus Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

How the Company Makes Money

Medexus Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include proprietary and licensed treatments for various conditions. The company has established key revenue streams through direct sales to healthcare providers and partnerships with other pharmaceutical companies for product distribution and co-marketing agreements. Additionally, Medexus benefits from government and private insurance reimbursements for its medications, which further contributes to its earnings. Significant partnerships with healthcare organizations and ongoing investment in research and development also play a crucial role in driving the company's revenue growth, as they enable Medexus to expand its portfolio and reach new markets.

Medexus Pharmaceuticals Inc Financial Statement Overview

Summary

Strong recent cash generation (TTM operating cash flow ~$17.4M; free cash flow ~$17.2M) and improved leverage (debt-to-equity ~0.40) support financial stability. Offsetting this, profitability remains thin/near breakeven (TTM net income slightly negative) and past cash-flow volatility increases execution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue grew ~5.1% to ~$109.4M, with a solid gross margin (~53%) and positive EBITDA margin (~15.6%), indicating healthy product economics. However, profitability is still fragile: TTM net income is slightly negative, and operating profit is modest versus revenue, suggesting elevated operating costs and limited cushion if demand softens. Overall, the trend shows meaningful improvement from earlier losses, but earnings consistency remains a key gap.

Balance Sheet

Leverage has improved materially: total debt declined from prior years and the latest debt-to-equity is ~0.40 (TTM), with equity around ~$52.2M. That said, the company previously ran with much higher leverage (debt-to-equity above 1.6–4.2 in prior annual periods), highlighting historical balance-sheet risk and the importance of maintaining the recent deleveraging trajectory. Returns on equity are currently low, consistent with still-thin net profitability.

Cash Flow

Cash generation is a clear strength: TTM operating cash flow is ~$17.4M and free cash flow is ~$17.2M, with positive free-cash-flow growth (~7.6%). Free cash flow is strong relative to reported earnings, reflecting good cash conversion and helping support debt reduction and financial flexibility. The main watch item is volatility in earlier periods (including negative operating/free cash flow in 2022–2023), though the recent profile is notably stronger.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	109.42M	108.33M	113.05M	108.10M	76.70M	79.66M
Gross Profit	53.57M	56.58M	59.51M	60.04M	37.93M	42.01M
EBITDA	17.35M	16.81M	19.28M	16.14M	15.16M	-23.61M
Net Income	-240.45K	2.25M	-214.00K	1.22M	-2.88M	-28.26M
Balance Sheet
Total Assets	154.98M	171.84M	155.73M	161.33M	139.22M	148.51M
Cash, Cash Equivalents and Short-Term Investments	14.97M	23.97M	5.25M	13.07M	10.02M	18.70M
Total Debt	25.35M	37.18M	49.90M	94.72M	54.86M	56.40M
Total Liabilities	102.77M	119.69M	125.41M	187.70M	151.82M	130.50M
Stockholders Equity	52.21M	52.14M	30.32M	22.45M	17.79M	18.02M
Cash Flow
Free Cash Flow	17.16M	21.31M	18.45M	-1.81M	-8.89M	-5.72M
Operating Cash Flow	17.36M	24.03M	18.71M	-1.44M	-1.18M	5.04M
Investing Cash Flow	-11.48M	-6.00M	-3.48M	-1.72M	-8.20M	-11.70M
Financing Cash Flow	418.00K	796.00K	-23.05M	6.41M	663.00K	18.68M

Medexus Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Positive. The current price of 3.15 is above the 20-day moving average (MA) of 2.88, above the 50-day MA of 2.87, and above the 200-day MA of 2.86, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 70.35 is Negative, neither overbought nor oversold. The STOCH value of 78.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDP.

Medexus Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	76 Outperform	C$177.18M	12.11	22.35%	1.60%	22.22%	25.50%
MDP	68 Neutral	C$101.75M	211.50	0.87%	―	2.14%	-83.06%
VEXT	59 Neutral	C$61.92M	-6.17	-21.73%	―	43.56%	-349.41%
MPH	54 Neutral	C$11.69M	-2.12	-18.39%	―	24.30%	-68.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VM	46 Neutral	C$26.79M	-5.29	-256.01%	―	―	―
BNXT	42 Neutral	C$73.09M	-16.32	―	―	-62.34%	9.80%

Medexus Pharmaceuticals Inc Corporate Events

Medexus Sets Date for Q3 2026 Earnings Call and Webcast

Medexus Pharmaceuticals has scheduled a conference call on February 12, 2026, to discuss its financial results for the third fiscal quarter ended December 31, 2025, with financial statements and management’s discussion and analysis to be filed after markets close on February 11. The company will provide both a live webcast and replay of the call through its investor relations website, signaling continued transparency with shareholders and stakeholders as it reports on its performance in the specialty and rare-disease pharmaceutical market.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.